Multiple primitive intracranial tumors with different histological characteristics are uncommon. Although coexistence of a medulloblastoma with glial tumors has been reported in children, medulloblastoma is rarely found in adults, especially those older than 40 years of age. We present an extremely rare case of a medulloblastoma developing in a 40-year-old male undergoing maintenance chemotherapy for anaplastic astrocytoma for 21 months after radiotherapy. Initially, he complained of intractable epilepsy characterized by complex partial seizures. Magnetic resonance imaging (MRI) revealed a slightly enhanced mass lesion in the left insula region. He underwent subtotal removal of the tumor and it was histologically diagnosed as anaplastic astrocytoma. After 19 months of treatment with temozolomide (TMZ) and radiotherapy, he presented with vertigo and headache. A homogeneously enhanced mass had developed in the left cerebellar hemisphere. He received gross total resection of the second tumor, pathologically diagnosed as medulloblastoma. In conclusion, this is the first case report of an adult medulloblastoma coexisting with anaplastic astrocytoma.
InTRoduCTIon
Multiple primitive intracranial tumors with different histological characteristics are rare, and only two cases of medulloblastoma coexisting with glial tumors (both consisting of medulloblastoma and juvenile pilocytic astrocytoma) have so far been reported in the pediatric departments (2, 13). Medulloblastoma is rare in adults, and is even more rare in patients older than 40 years of age (1, 5, 14, 16) . We encountered a case where a medulloblastoma developed in an adult patient at the age of 40 while he was undergoing maintenance chemotherapy for anaplastic astrocytoma in the brain 19 months after radiotherapy. This is the first case report of an adult showing a medulloblastoma coexisting with an anaplastic astrocytoma in the brain.
CASE REPoRT
A 38-year-old male was referred to our department in August 2006 for intractable epilepsy characterized by complex partial seizures. Computed tomography (CT) and magnetic resonance imaging (MRI) with prior gadolinium (Gd) treatment revealed a slightly enhanced mass lesion in the left insula region ( Figure 1A-C) . The tumor was subtotally removed using intracranial electrodes for functional mapping, because the tumor was located in an anatomical site with limited accessibility. Pathological findings revealed the tumor to be an anaplastic astrocytoma (Figure 2A,B) . We administered radiotherapy plus continuous daily temozolomide orally (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy) ( Figure 3A Figure 5A-D) . After total tumor removal from the cerebellum, pathological examination identified the specimen as a medulloblastoma ( Figure 6A,B) . He received additional craniospinal irradiation (whole brain: 18 Gy; whole spine: 27 Gy; total: 54 Gy extended locally to the posterior fossa) with oncovin, followed up by periodic chemotherapy (etoposide, cisplatine) at our hospital without any neurological deficit. Follow-up MRI was performed after every chemotherapy course (every 8 weeks). Six months later (after three courses of chemotherapy), follow-up MRI revealed a newly developed homogeneously enhanced mass that extended in the right frontal lobe and right posteotemporal lobe with a perifocal edema ( Figure 7A ,B). Removal of tumor followed by specimen examination revealed the specimen as an anaplastic oligoastrocytoma. When all available versions of effective adjuvant therapies were exhausted, the patient died in November 2009.
dISCuSSIon
This case report is extremely rare in terms of the coexistence tumor, because of discrepancies in the diagnosis criteria and features when compared with previously reported cases, although the secondary tumor (medulloblastoma) was sited inside the previously irradiated field. Molecular abnormalities, oncogenes or defective tumor-suppressor genes of medulloblastomas and astrocytomas patients have recently been investigated; however, corresponding molecular data of the present patient are not known. The potential factors responsible for the development of multiple primary brain tumors remain unknown, further studies in elucidating the relevant factors are warranted. In addition, the more complex multifactors inducing tumorigenesis have to be clarified in order to resolve the mechanism(s) of multiple primary brain tumors.
ConCLuSIonS
To our knowledge, this is the first case report of a medulloblastoma coexisting with a malignant astrocytoma in a 40-year-old patient who has undergone maintenance chemotherapy for anaplastic astrocytoma 19 months after radiotherapy. Complex multi-factors inducing tumorigenesis have to be clarified in order to understand the mechanism and treatment of multiple primary brain tumors. older than 16-18 years of age (1, 5, 14, 16) . Among the defined adult medulloblastoma patients, only 20% of the cases are more than 40 years of age (14) . Adult medulloblastoma itself is quite rare, and coexistence of adult medulloblastoma with glioma is even more or extremely rare. Moreover, anaplastic astrocytoma is far more malignant than piloctic astrocytoma, and the present patient in fact died of uncontrollable anaplastic astrocytoma.
The possible explanations for occurrence of multiple diverse primary brain tumors in this extremely rare case include: (I) secondary brain tumor induction by radiation; (II) tumorigenetic activities of certain oncogenes; and (III) defects in tumor suppressor genes. Hitherto, there are only six reported rare cases of radiation-induced medulloblastoma compared to the many radiation-induced glioma cases documented (6, 10, 11, 12, 17) . According to the modified Cahan's criteria for radiation-induced tumors: (i) The onset of secondary tumors is sited in the previously irradiated field; (ii) both the primary and secondary tumors are histologically different from each other; and (iii) a sufficiently long latency period (ca. 5 years) exists from the point of irradiation termination to the onset of a secondary tumor (7) . The latency period of the secondary tumor onset (ca. 5 years) is attributable to the underlying mechanism of carcinogenesis triggered by irradiationinduced partial DNA injury (i.e. to the degree of not killing the cell but inducing abnormalities in DNA strands with defects in tumor-suppressor genes or oncogenes controlling the cell replication cycle) (4, 15). In previously reported second malignant brain tumors, the onsets of glioblastomas and sarcomas range respectively within 5 to 15 and 4 to 15 years after the initial exposure to radiation (4, 15). All the three previously documented cases of radiation-induced medulloblastoma indicated a post-irradiation latency period of 8 to 41 years (average 22.0 years); a finding that shows the marked discrepancy with our present case of 19 months. In our case, the medulloblastoma was not considered to be a radiation-induced A B
